Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
Centre Hospitalier Regional et Universitaire de Lille
Lila, FranciaPublications en collaboration avec des chercheurs de Centre Hospitalier Regional et Universitaire de Lille (63)
2024
-
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235
-
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595
-
Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
Bone Marrow Transplantation, Vol. 59, Núm. 7, pp. 965-973
2023
-
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422
-
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014
-
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia
Seminars in Hematology
2022
-
Correction to: The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study
The American journal of gastroenterology, Vol. 117, Núm. 5, pp. 818
-
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis (Advances in Therapy, (2022), 39, 5, (1976-1992), 10.1007/s12325-022-02083-8)
Advances in Therapy
-
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322
Annals of oncology : official journal of the European Society for Medical Oncology
-
Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))
Annals of Oncology
-
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
European Journal of Cancer, Vol. 174, pp. 221-231
-
Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort
Neuro-oncology, Vol. 24, Núm. 10, pp. 1726-1735
-
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood, Vol. 140, Núm. 11, pp. 1229-1253
-
The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study
American Journal of Gastroenterology, Vol. 117, Núm. 2, pp. 301-310
-
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
Advances in Therapy, Vol. 39, Núm. 5, pp. 1976-1992
2021
-
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)
American Journal of Hematology, Vol. 96, Núm. 1, pp. 69-79
-
Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis
Journal of Hepatology, Vol. 75, Núm. 4, pp. 912-923
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212